Showing 1241-1250 of 1616 results for "".
- Wolfe Eye Clinic Performs First Surgery in Clinical Trial Evaluating an Investigational Gene Therapy for Geographic Atrophy Secondary to Dry AMDhttps://modernod.com/news/wolfe-eye-clinic-performs-first-surgery-in-clinical-trial-evaluating-an-investigational-gene-therapy-for-geographic-atrophy-secondary-to-dry-amd/2478676/Wolfe Eye Clinic announced today that Jared Nielsen, MD, Retina Disease Specialist at Wolfe Eye Clinic, was recently the third surgeon in the United States and first in the Midwest to perform surgery in a clinic trial evaluating an i
- Equinox Ophthalmic Appoints Stuart Raetzman as Executive Chairhttps://modernod.com/news/equinox-ophthalmic-appoints-stuart-raetzman-as-executive-chair/2478384/Equinox Ophthalmic announced the appointment of Stuart Raetzman as Executive Chairman. Company founder, John Berdahl, MD, will continue to serve on the Board of Directors and as Chief Medical Officer. Equinox Ophthalmic is a company focused on addressing the unmet need in glau
- Fauci Says He’s ‘Cautiously Optimistic’ About Moderna COVID-19 Vaccinehttps://modernod.com/news/fauci-says-hes-cautiously-optimistic-about-moderna-covid-19-vaccine/2477860/Infectious disease expert Anthony Fauci, MD, says he’s “cautiously optimistic” about biotech company Moderna’s COVID-19 vaccine candidate, according to a FierceHealthcare
- AAO Releases Statement Addressing the Reopening of Ophthalmology Carehttps://modernod.com/news/aao-releases-statement-regarding-returning-to-ophthalmology-practice/2477611/In a letter to its membership, American Academy of Ophthalmology (AAO) CEO David W. Parke II, MD, stated that now is the time to consider the process of reopening ophthalmology care—on a local
- Trump to Nominate Stephen Hahn, Cancer Researcher, to Head FDAhttps://modernod.com/news/trump-to-nominate-stephen-hahn-cancer-researcher-to-head-fda/2477068/President Trump said Friday that he intended to nominate Stephen M. Hahn, MD, a top executive at The University of Texas M.D. Anderson Cancer Center, to be the next commissioner of the Food and Drug Administration, according to a
- Kodiak Sciences Announces Presentation of Durability Data from Clinical Development Program of KSI-301 in Wet AMD, DME, and RVO at AAOhttps://modernod.com/news/kodiak-sciences-announces-presentation-of-durability-data-from-clinical-development-program-of-ksi-301-in-wet-amd-dme-and-rvo-at-aao/2476945/Kodiak Sciences announced that Charles C. Wykoff, MD, PhD, will present first-time results at the annual mneeting of the American Academy of Ophthalmology (AAO) to be held in San Francisco. The Retina Subspecialty Day (
- Clinreg Consulting Services Appoints New President and Plans to Expand Consulting Teamhttps://modernod.com/news/clinreg-consulting-services-appoints-new-president-and-plans-to-expand-consulting-team/2476920/Clinreg Consulting Services, a provider of regulatory, clinical, statistical, data management, and quality consulting services, announced the appointment of Lee Kramm, MD, MSE, as President and plans to expand its con
- Study Probes ODs’ Attitudes About Blue-Light Blocking Deviceshttps://modernod.com/news/study-probes-ods-attitudes-about-blue-light-blocking-devices/2476599/A recent study found that optometrists remain split on the impact of blue light from electronic devices, such as computer and phone screens, and the effectiveness of blue light-blocking devices, according to reporting by Patrick Campbell in MD Magazine, as
- Aldeyra Therapeutics to Present Phase 2b Dry Eye Disease Results at ARVOhttps://modernod.com/news/aldeyra-therapeutics-to-present-phase-2b-dry-eye-disease-results-at-arvo/2476456/Aldeyra Therapeutics announced that John Sheppard, MD, Professor of Ophthalmology at Eastern Virginia Medical School, will present results of the phase 2b clinical trial of topical reproxalap in dry eye disea
- Ivantis Announces 24-Month Results of Comparative MIGS Clinical Trialhttps://modernod.com/news/ivantis-announces-24-month-results-of-landmark-prospective-randomized-comparative-migs-clinical-trial/2476379/Ivantis, developer of the Hydrus Microstent, announced the 24-month results of the COMPARE study for minimally invasive glaucoma surgery (MIGS). Results from the study were presented by Thomas Samuelson, MD, President of the American Society of Cataract and Refracti